Discover 468 paid clinical trials in Grand Rapids, Michigan. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 468
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
for
Recurrent Lung Non-Small Cell Carcinoma,
Location: Lansing MI, Chelsea MI, Brighton MI, Flint MI,
Sponsor: SWOG Cancer Research Network
Sex: All
Age: 18+
Code: NCT06616584
Phase 2, Phase 3, Recruiting
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
for
Castration-Resistant Prostate Carcinoma,
Location: Lansing MI, Saginaw MI, Chelsea MI, Brighton MI,
Sponsor: SWOG Cancer Research Network
Sex: Male
Age: 18+
Code: NCT06470243
Phase 3, Recruiting
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
for
Metastatic Renal Cell Carcinoma,
Location: Lansing MI, Chelsea MI, Brighton MI, Ann Arbor MI,
Sponsor: NRG Oncology
Sex: All
Age: 18+
Code: NCT05327686
Phase 2, Recruiting
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
for
Mantle Cell Lymphoma
Location: Lansing MI, Mount Pleasant MI, Saginaw MI, Chelsea MI,
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All
Age: 60+
Code: NCT05976763
Phase 3, Recruiting
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
for
Recurrent Lung Non-Small Cell Carcinoma,
Location: Lansing MI, Saginaw MI, Chelsea MI, Brighton MI,
Sponsor: SWOG Cancer Research Network
Sex: All
Age: 18+
Code: NCT05642572
Phase 2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial
for
Metastatic Colorectal Adenocarcinoma,
Location: Lansing MI, Chelsea MI, Brighton MI, Flint MI,
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All
Age: 18+
Code: NCT05673148
Phase 2, Recruiting
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Location: Lansing MI, Saginaw MI, Chelsea MI, Brighton MI,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT04181060
Phase 3, Recruiting
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
for
Malignant Female Reproductive System Neoplasm,
Location: Lansing MI, Chelsea MI, Brighton MI, Flint MI,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06126276
Phase 2, Recruiting
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Location: Lansing MI, Jackson MI, Saginaw MI, Chelsea MI,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT03866382
Phase 2, Recruiting
The Long-term Safety and Effectiveness Evaluation of the QDOT MICRO System Use in Conjunction With VISITAG SURPOINT Module for the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation.
Sponsor: Heart Rhythm Clinical and Research Solutions, LLC
Sex: All
Age: 18+
Code: NCT06324201
Recruiting
Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment
for
Multiple Myeloma and Plasma Cell Neoplasm
Location: Lansing MI
Sponsor: Sparrow Regional Cancer Center
Sex: All
Age: 18+
Code: NCT00389701
Phase 2, Recruiting
Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement